We can't find the internet
Attempting to reconnect
14450.2;3 PFLS-LS
A robust CHO cell-based process platform for rapid manufacture of novel fully human bispecific monoclonal antibodies with importance for preclinical studies, immuno- and cancer therapies
Résumé
A robust CHO cell-based process platform for rapid manufacture of novel fully human bispecific monoclonal antibodies with importance for preclinical studies, immuno- and cancer therapies
Textes supplémentaires
Abstract
The project aims to establish a robust commercial-scale manufacturing platform for the kappa lambda body (¿Û¿Ü-body), a novel fully human bispecific antibody format. This new generation of biotherapeutics considerably extends the application fields of current classical monoclonal antibodies. In order to ensure process robustness and rapid production, a chemically defined minimal culture medium and single-use bioreactors are to be used. The 4 project partners will demonstrate the platform¡¿s suitability for one candidate ¿Û¿Ü-body, which will be correctly glycosylated and folded, with > 2.5 g L-1 of total antibody.
Participants
Regine Eibl
Kontaktperson
regine.eibl@zhaw.ch
Zürcher Hochschule für Angewandte W ZHAW Regine Eibl Campus Grüntal Dep. für Life Sciences & Facili 8820 Wädenswil ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2013-05-31
- Date de fin
- 2015-03-09
- Coûts totaux approuvés
- CHF 352952.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- T490 Biotechnology 100.0%